BioPharmSignal logoBioPharmSignal

Biotech News

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Artelo Biosciences (ARTL)Artelo BiosciencesFinancing

ARTL (ARTL) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is artl.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

ARTLArtelo Biosciences2026-06-29 12:45 EST

Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026

ARTLArtelo Biosciences2026-07-01 12:42 EST

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

ERASErasca2026-07-13 20:19 EST

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZNTLZentalis2026-08-14 02:23 EST

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

ERASErasca2026-07-14 03:10 EST

Erasca Announces Pricing of Upsized Public Offering of Common Stock

View all latest news

Artelo Biosciences

Lipid-Signaling Therapeutics Artelo Biosciences develops medicines that modulate cannabinoid and fatty-acid signaling pathways. Its portfolio addresses cancer supportive care, pain and neuropsychiatric conditions through distinct small-molecule mechanisms. ART27.13 ART27.13 is a peripherally selective cannabinoid-receptor agonist in...

Recent company news

ARTLArtelo Biosciences2026-08-20 12:52 EST

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

ARTLArtelo Biosciences2026-08-17 12:52 EST

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

ARTLArtelo Biosciences2026-08-13 12:00 EST

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

ARTLArtelo Biosciences2026-08-10 12:47 EST

Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma

ARTLArtelo Biosciences2026-07-22 12:39 EST

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition

Stock data

Close
0.69 USD
Market cap
5.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States